Jason M. Hafron, director of research at the Michigan Institute of Urology, was taken aback by the results of a study he was conducting: the vast majority of patients with prostate cancer who need regular injections to suppress their testosterone levels didn’t get treated on time.
Do multi-cancer detection tests provide a net benefit? NCI aims to answer this question, beginning with the Vanguard feasibility trial which recently started accruing patients.
